To redirect T cells against tumor cells, T cells can be engineered ex vivo to express cancer-
antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T …

Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-
ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable …

In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …

Chimeric antigen receptor (CAR)-T cell therapy represents a landmark advance in
personalized cancer treatment. CAR-T strategy generally engineers T cells from a specific …

Immune escape is a hallmark of cancer. The dynamic and heterogeneous tumour
microenvironment (TME) causes insufficient infiltration and poor efficacy of natural killer (NK) …

Simple Summary Aberrant glycosylation is a common feature of many cancers, and it plays
crucial roles in tumor development and biology. Cancer progression can be regulated by …

Abstract Purpose The claudin 18.2 (CLDN18. 2) antigen is frequently expressed in
malignant tumors, including pancreatic ductal adenocarcinoma (PDAC). Although CLDN18 …

In many hematologic malignancies, the adoptive transfer of chimeric antigen receptor (CAR)
T cells has demonstrated notable success; nevertheless, further improvements are …

The clinical use of cellular immunotherapies is gaining momentum and the number of
approved indications is steadily increasing. One class of cellular therapies—chimeric …

In recent years, the incidence of colorectal cancer (CRC) and breast cancer (BC) has
increased worldwide and caused a higher mortality rate due to the lack of selective anti …